Latest News About Marty Makary

Here’s a concise update based on recent reporting up to May 2026.

• Marty Makary has been in the public eye largely for his role as a physician and commentator on health policy. Multiple outlets noted his nomination to lead the FDA in late 2024, with coverage highlighting his stance on COVID-19 measures and his track record as a critic of some public-health policies during the pandemic.[1][3][5]
• He was confirmed as FDA commissioner in early 2025, and subsequent reporting described his agenda as modernizing regulatory processes and exploring AI-assisted review tools, while also noting scrutiny from lawmakers about his pandemic-era positions.[2][3]
• By March 2026, coverage began shifting toward his governance leadership and the challenges the agency faces, including how to balance rapid approvals with safety oversight, and how his prior views on vaccines, therapeutics, and public health policy would influence FDA decisions.[3][4]

If you want, I can pull specific articles or summarize his policy positions and notable statements with direct quotes and dates. Would you like a focused timeline or a quick pros/cons snapshot of his FDA tenure?

Citations:

• Coverage of Makary’s FDA nomination and public stance on COVID-19 measures[1]
• Confirmation as FDA commissioner and stated priorities[2]
• Contemporary assessments of his leadership and policy implications[4][5][3]